Consolidated Financial Highlights | |||||
(In INR Crores) | |||||
Particulars | Q1 FY24 | Q1 FY23 | YoY Growth | Q4 FY23 | QoQ Growth |
Revenue from Operation | 1,749 | 1,482 | 18 % | 2,164 | -19 % |
CDMO | 898 | 770 | 17 % | 1,285 | -30 % |
Complex Hospital Generic (CHG) | 617 | 508 | 22 % | 702 | -12 % |
| 239 | 211 | 13 % | 206 | 16 % |
EBITDA | 171 | 89# | 92 % | 376 | -55 % |
EBITDA Margin | 10 % | 6 % | 17 % | ||
PAT | -99 | -109 | NA | 50 | -297 % |
PAT Margin | -6 % | -7 % | 2 % |
# Q1 FY23 EBITDA had one-time inventory margin impact of INR
Key Highlights for Q1FY24
- Revenue from Operation grew by 18% YoY in Q1FY24 driven by broad base performance across all three businesses – CDMO, CHG and ICH
- EBITDA margin in Q1FY24 was 10%, a YoY improvement compared to 6% in Q1FY23, driven by healthy revenue growth and cost optimization measures
- We maintain our quality track record of zero OAIs (Official Action Indicated) as we successfully closed the
US FDA inspection at the Pithampur facility with zero observations - We strengthened our Management Team by appointing
Jeffrey Hampton as President & Chief Operating Officer for Piramal Critical Care (CHG business) - We have shared the details of our Rights Issue - Rights Price of INR. 81, Record Date of
August 2, 2023 and Entitlement Ratio of 5:46
Historically our H2 has been better than H1, both in terms of revenue and profitability. We are working to leverage our good start to the financial year and continuing this momentum to deliver a healthy YoY performance for the rest of the year. We believe in the growth potential of our business and are accordingly executing on our strategic priorities to create shareholder value. Our promoter and promoter group have agreed to subscribe to the extent of 100% of the equity shares offered in our Rights Issue, thereby reaffirming their confidence in the underlying strengths of our business."
Key Business Highlights for Q1FY24 |
Complex Hospital Generics (CHG):
|
Consolidated Profit and Loss Statement | |||||
(In INR Crores) | |||||
Reported Financials | |||||
Particulars | Q1FY24 | Q1FY23 | YoY Change | Q4FY22 | QoQ Change |
Revenue from Operations | 1,749 | 1,482 | 18 % | 2,164 | -19 % |
Other Income | 38 | 72 | -47 % | 25 | 56 % |
Total Income | 1,787 | 1,554 | 15 % | 2,188 | -18 % |
Material Cost | 627 | 574 | 9 % | 840 | -25 % |
Employee Expenses | 496 | 461 | 8 % | 474 | 5 % |
Other Expenses | 494 | 430 | 15 % | 499 | -1 % |
EBITDA | 171 | 89# | 92 % | 376 | -55 % |
Finance Cost | 119 | 62 | 90 % | 104 | 14 % |
Depreciation | 174 | 162 | 7 % | 184 | -6 % |
Share of net profit of associates | 14 | 20 | -28 % | 8 | 85 % |
Profit Before Tax | -107 | -115 | -7 % | 95 | -213 % |
Tax | -9 | -6 | NA | 45 | -119 % |
Net Profit after Tax | -99 | -109 | NA | 50 | -297 % |
Exceptional item | 0 | 0 | 0 | ||
Net Profit after Tax after exceptional item | -99 | -109 | NA | 50 | -297 % |
# Q1 FY23 EBITDA had one-time inventory margin impact of INR
Q1FY24 Earnings Conference Call
The dial-in details for the call are as under:
Event | Location & Time | Telephone Number |
Conference call on | +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) | |
1 800 120 1221 (Toll free number) | ||
(Eastern Time – | Toll free number 18667462133 | |
(London Time) | Toll free number 08081011573 | |
(Singapore Time) | Toll free number 8001012045 | |
(Hong Kong Time) | Toll free number 800964448 | |
Express Join with Diamond Pass™ | Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9503078&linkSecurityString=33aa158d84 |
About
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635) , offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes
For more information visit: www.piramaI.com/pharma I I inker1ln | Facebook I Twitter.
Photo: https://mma.prnewswire.com/media/2169456/Nandini_Piramal.jpg
Logo: https://mma.prnewswire.com/media/1855206/4196563/Piramal_Pharma_Limited_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy24-301893264.html
SOURCE
© Canada Newswire, source